Prosthetic Joint Infection Drug Granted Orphan Drug Designation
The US Food and Drug Administration granted Orphan Drug Designation to NP-2092 (TenNor Therapeutics), a multitargeting drug conjugate, for the treatment of prosthetic joint infections.
According to a press release from the company, biofilm infections associated with medical devices, such as prosthetic joint, are becoming more common and remain difficult and costly to treat.
TNP-2092 had previously received FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for TNP-2092.
Read the full press release here.